Regulus Therapeutics (RGLS) Misses Q2 EPS by 5c

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.17), $0.05 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Obsidian Energy Increases Syndicated Credit Facility
• Worthington Industries (WOR) Misses Q4 EPS by 9c